Jevtana
Sanofi’s Jevtana doubles progression-free survival in metastatic castration-resistant prostate cancer
October 1, 2019Manufacturing and Production, Research and Development ESMO 2019, Jevtana, Sanofi, pharma, prostate cancer
Sanofi was present at the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona this year to reveal new …
Scottish Medicines Consortium approves Sanofi’s prostate cancer drug
December 12, 2016Manufacturing and Production, Sales and Marketing Jevtana, Sanofi, prostate cancer
Sanofi’s speciality care global business unit Sanofi Genzyme has announced that the Scottish Medicines Consortium has accepted the company’s Jevtana …
NICE recommends Jevtana for advanced prostate cancer
May 25, 2016Sales and Marketing Jevtana, NICE, approval, prostate cancer, recommendation
The National Institute for Health and Care Excellence (NICE) has recommended Sanofi Genzyme’s Jevtana (cabazitaxel), in combination with prednisone or …
A win for Sanofi on Jevtana after NICE reverses guidance
April 22, 2016Medical Communications, Sales and Marketing Cancer Drugs Fund, Jevtana, NICE, Sanofi, recommendation, reversal
Prostate cancer treatment Jevtana (cabazitaxel), marketed by Sanofi (NYSE: SNY) has been recommended by NICE in its final guidance. The …
Oncologists say CDF cuts will compromise treatment
March 10, 2015Sales and Marketing CDF, Jevtana, NHS, NICE, Sanofi, cabazitaxel, doctors.net, m3
Oncologists believe cutting drugs from the Cancer Drugs Fund won’t save the NHS money and will worsen patient outcomes according …
Half of UK population will get cancer
February 4, 2015Research and Development, Sales and Marketing CDF, CRUK, Cancer, Jevtana, Sanofi, cabazitaxel
New figures from Cancer Research UK (CRUK) suggest that one in two people will develop cancer at some point in …
NHS drops 25 treatments from Cancer Drugs Fund
January 12, 2015Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus
Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …
Exclusive: Novartis drug struck off cancer drugs fund
January 8, 2015Sales and Marketing Afinitor, Jevtana, NHS, NHS England, NICE, Novartis, Sanofi, everolimus
Novartis’ Afinitor (everolimus) will be removed from the Cancer Drugs Fund list when NHS England announces which drugs it can …
Sanofi cleared in sales row
September 20, 2012Medical Communications, Sales and Marketing ABPI, CDF, Jevtana, PMCPA, Sanofi
Sanofi has been cleared of any wrongdoing after allegations that it had broken multiple clauses in the ABPI Code of …
Price cut sways NICE on Zytiga
May 16, 2012Sales and Marketing Jevtana, NICE, Zytiga, prostate cancer
NICE is recommending Janssen’s prostate cancer pill Zytiga, reversing its previous stance. In its final guidance, the watchdog is recommending …
NICE rejects Sanofi’s Jevtana
January 12, 2012Sales and Marketing Jevtana, NICE, Sanofi, Zytiga
NICE is not recommending Sanofi’s prostate cancer drug Jevtana due to its high cost and questions over its safety. In …
Key product launches of 2011
December 19, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products
Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …
NICE refuses to back Sanofi’s Jevtana
September 30, 2011Sales and Marketing Jevtana, NICE
NICE has not recommended Sanofi’s prostate cancer drug Jevtana due to its high cost and concerns over its safety data. …
European approval for prostate cancer drug Zytiga
September 8, 2011Sales and Marketing Janssen, Jevtana, Johnson & Johnson, Zytiga, prostate cancer
Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer. Zytiga (abiraterone acetate) is now licenced …
Sanofi launches Jevtana in UK
July 6, 2011Sales and Marketing Jevtana, Sanofi, prostate cancer
Sanofi has launched its promising advanced prostate cancer drug Jevtana in the UK following EMA approval in March. Jevtana (cabazitaxel) …
